Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Martin Reck

Showing results (181-190 of 437) with videos related to

Pageof 44
Sort By:
ESMO Open|August 2, 2017
Time since start of first-line therapy as a predictive clinical marker for nintedanib in patients with previously treated non-small cell lung cancerBirgit Gaschler-Markefski, Patricia Sikken, John V Heymach, et al.
Lung Cancer (Amsterdam, Netherlands)|March 2, 2010
Sunitinib in combination with gemcitabine plus cisplatin for advanced non-small cell lung cancer: a phase I dose-escalation studyMartin Reck, Norbert Frickhofen, Susana Cedres, et al.
Lung Cancer (Amsterdam, Netherlands)|October 10, 2012
Baseline quality of life and performance status as prognostic factors in patients with extensive-stage disease small cell lung cancer treated with pemetrexed plus carboplatin vs. etoposide plus carboplatinMartin Reck, Nick Thatcher, Egbert F Smit, et al.
Clinical Lung Cancer|August 3, 2024
Treatment-Switching Adjustment of Overall Survival in CheckMate 227 Part 1 Evaluating First-Line Nivolumab Plus Ipilimumab Versus Chemotherapy for Metastatic Nonsmall Cell Lung CancerMartin Reck, Tuli De, Luis Paz-Ares, et al.
Clinical Lung Cancer|February 3, 2024
STAR-121: A Phase III Randomized Study of Domvanalimab and Zimberelimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy in Untreated Metastatic Non-Small Cell Lung Cancer With No Actionable Gene AlterationsDelvys Rodriguez-Abreu, Joaquim Bosch-Barrera, Jhanelle E Gray, et al.
Future Oncology (London, England)|May 30, 2023
TROPION-Lung08: phase III study of datopotamab deruxtecan plus pembrolizumab as first-line therapy for advanced NSCLCBenjamin P Levy, Enriqueta Felip, Martin Reck, et al.
Frontiers in Oncology|February 11, 2020
The Multi-Modal Effect of the Anti-fibrotic Drug Pirfenidone on NSCLCSebastian Marwitz, Kati Turkowski, Dörte Nitschkowski, et al.
The Lancet. Oncology|November 13, 2025
Effectiveness of NELSON versus PLCOm2012 lung cancer screening eligibility criteria in Germany (HANSE): a prospective cohort studyJens Vogel-Claussen, Benjamin-Alexander Bollmann, Katharina May, et al.
Journal of Thoracic Disease|June 11, 2019
Circulating free tumor-derived DNA to detect <i>EGFR</i> mutations in patients with advanced NSCLC: French subset analysis of the ASSESS studyMarc G Denis, Marie-Pierre Lafourcade, Gwenaëlle Le Garff, et al.
The Lancet. Respiratory Medicine|April 13, 2020
Challenges in lung cancer therapy during the COVID-19 pandemicLuana Calabrò, Solange Peters, Jean-Charles Soria, et al.
Pageof 44

Showing results (181-190 of 437) with videos related to

Sort By:
Pageof 44
ESMO Open|August 2, 2017
Time since start of first-line therapy as a predictive clinical marker for nintedanib in patients with previously treated non-small cell lung cancerBirgit Gaschler-Markefski, Patricia Sikken, John V Heymach, et al.
Lung Cancer (Amsterdam, Netherlands)|March 2, 2010
Sunitinib in combination with gemcitabine plus cisplatin for advanced non-small cell lung cancer: a phase I dose-escalation studyMartin Reck, Norbert Frickhofen, Susana Cedres, et al.
Lung Cancer (Amsterdam, Netherlands)|October 10, 2012
Baseline quality of life and performance status as prognostic factors in patients with extensive-stage disease small cell lung cancer treated with pemetrexed plus carboplatin vs. etoposide plus carboplatinMartin Reck, Nick Thatcher, Egbert F Smit, et al.
Clinical Lung Cancer|August 3, 2024
Treatment-Switching Adjustment of Overall Survival in CheckMate 227 Part 1 Evaluating First-Line Nivolumab Plus Ipilimumab Versus Chemotherapy for Metastatic Nonsmall Cell Lung CancerMartin Reck, Tuli De, Luis Paz-Ares, et al.
Clinical Lung Cancer|February 3, 2024
STAR-121: A Phase III Randomized Study of Domvanalimab and Zimberelimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy in Untreated Metastatic Non-Small Cell Lung Cancer With No Actionable Gene AlterationsDelvys Rodriguez-Abreu, Joaquim Bosch-Barrera, Jhanelle E Gray, et al.
Future Oncology (London, England)|May 30, 2023
TROPION-Lung08: phase III study of datopotamab deruxtecan plus pembrolizumab as first-line therapy for advanced NSCLCBenjamin P Levy, Enriqueta Felip, Martin Reck, et al.
Frontiers in Oncology|February 11, 2020
The Multi-Modal Effect of the Anti-fibrotic Drug Pirfenidone on NSCLCSebastian Marwitz, Kati Turkowski, Dörte Nitschkowski, et al.
The Lancet. Oncology|November 13, 2025
Effectiveness of NELSON versus PLCOm2012 lung cancer screening eligibility criteria in Germany (HANSE): a prospective cohort studyJens Vogel-Claussen, Benjamin-Alexander Bollmann, Katharina May, et al.
Journal of Thoracic Disease|June 11, 2019
Circulating free tumor-derived DNA to detect <i>EGFR</i> mutations in patients with advanced NSCLC: French subset analysis of the ASSESS studyMarc G Denis, Marie-Pierre Lafourcade, Gwenaëlle Le Garff, et al.
The Lancet. Respiratory Medicine|April 13, 2020
Challenges in lung cancer therapy during the COVID-19 pandemicLuana Calabrò, Solange Peters, Jean-Charles Soria, et al.
Pageof 44